Transgene SA (TRGNF) Discusses Progress in Individualized Neoantigen Therapeutic Vaccines and Expansion into Early-Stage NSCLC Transcript

Operator

Good morning, and welcome to the Transgene virtual key opinion leader event. At this time, all attendees are in a listen-only mode and a question-and-answer session will follow the formal presentation.

[Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Transgene website following the conclusion of the event.

Before I turn the call over to Alessandro Riva, Transgene’s Chairman and Chief Executive Officer, I’d like to remind everyone that today’s discussion contains forward-looking statements, which are subject to multiple risks and uncertainties. And with that, Alessandro, I’ll now pass it to you.

Alessandro Riva
CEO & Chairman of the Board

Thank you, and good afternoon and good morning, everyone. If you can move to the next slide. So it is a pleasure to share with you our progress in our Individualized Neoantigen Therapeutic Vaccine that is our main program, and we are focusing on this program since the last 3 years, and we have made significant progress, not only with our leading asset TG4050, but as you are going to hear today on the new program, that’s TG4070 in small — in non-small cell lung cancer.

So it is a pleasure to have with us today a leader in the oncology space that is Professor Nicolas Girard, who is Professor of Thoracic Oncology at Curie Institute Paris, and also other people of Transgene will join me as we present the advances in our portfolio.

So if I can go to the next